Abstract
Nanoparticles have been extensively employed to deliver many drugs, including siRNA, for the treatment of a variety of diseases, particularly cancer. Lately, there has been a great deal of effort to design nanoparticles with materials that are able to respond to intrinsic or extrinsic stimuli for “on demand” delivery of siRNA. These nanoparticles are able to trigger siRNA release upon different stimuli, such as a pH decrease, redox gradient, enzyme, light, magnetic field, temperature, ultrasound or electric current. Frequently, the stimuli cause the nanoparticles to undergo protonation, hydrolytic breakdown or phase transition for triggered release of siRNA, resulting in decreased side effects and better therapeutic outcome. While studies have demonstrated efficient in vitro and in vivo delivery, these “smart” nanoparticles have not yet reached the clinic. In this review, we address different classes of nanoparticles, such as polyplexes, lipoplexes, liposomes, polymeric micelles, polymeric, lipid and inorganic nanoparticles, that are able to respond to specific stimuli for siRNA triggered-release, emphasizing their application and discussing the latest advances.
Keywords: siRNA, nanoparticles, triggered release, environmental-responsive, drug delivery.
Current Pharmaceutical Design
Title:Stimuli-Responsive Nanoparticles for siRNA Delivery
Volume: 21 Issue: 29
Author(s): Josimar O. Eloy, Raquel Petrilli, Renata F. V. Lopez and Robert J. Lee
Affiliation:
Keywords: siRNA, nanoparticles, triggered release, environmental-responsive, drug delivery.
Abstract: Nanoparticles have been extensively employed to deliver many drugs, including siRNA, for the treatment of a variety of diseases, particularly cancer. Lately, there has been a great deal of effort to design nanoparticles with materials that are able to respond to intrinsic or extrinsic stimuli for “on demand” delivery of siRNA. These nanoparticles are able to trigger siRNA release upon different stimuli, such as a pH decrease, redox gradient, enzyme, light, magnetic field, temperature, ultrasound or electric current. Frequently, the stimuli cause the nanoparticles to undergo protonation, hydrolytic breakdown or phase transition for triggered release of siRNA, resulting in decreased side effects and better therapeutic outcome. While studies have demonstrated efficient in vitro and in vivo delivery, these “smart” nanoparticles have not yet reached the clinic. In this review, we address different classes of nanoparticles, such as polyplexes, lipoplexes, liposomes, polymeric micelles, polymeric, lipid and inorganic nanoparticles, that are able to respond to specific stimuli for siRNA triggered-release, emphasizing their application and discussing the latest advances.
Export Options
About this article
Cite this article as:
Eloy O. Josimar, Petrilli Raquel, Lopez F. V. Renata and Lee J. Robert, Stimuli-Responsive Nanoparticles for siRNA Delivery, Current Pharmaceutical Design 2015; 21 (29) . https://dx.doi.org/10.2174/1381612821666150901095349
DOI https://dx.doi.org/10.2174/1381612821666150901095349 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidant Effects and in vitro Cytotoxicity on Human Cancer Cell Lines of Flavonoid-Rich Flamboyant (<i>Delonix regia</i> (Bojer) Raf.) Flower Extract
Current Pharmaceutical Biotechnology Target Based Virtual Screening of New Leads Inhibitor against Bacterial Cell Division Protein FtsZ for the Discovery of Antibacterial Agents
Medicinal Chemistry Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis
Current Rheumatology Reviews Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry The Synthesis, Structure and Activity Evaluation of Secnidazole Derivatives as Helicobacter pylori Urease Inhibitors
Current Bioactive Compounds Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Mechanism and Anticancer Activity of the Metabolites of an Endophytic Fungi from Eucommia ulmoides Oliv
Anti-Cancer Agents in Medicinal Chemistry Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Clinical Applicability of Microarray Technology in the Diagnosis, Prognostic Stratification, Treatment and Clinical Surveillance of Cervical Adenocarcinoma
Current Pharmaceutical Design The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry miR-15b Suppression of Bcl-2 Contributes to Cerebral Ischemic Injury and is Reversed by Sevoflurane Preconditioning
CNS & Neurological Disorders - Drug Targets Alternative Splicing, DNA Damage and Modulating Drugs in Radiation Therapy for Cancer
Anti-Cancer Agents in Medicinal Chemistry Lipid Metabolism and Mitochondria: Cross Talk in Cancer
Current Drug Targets Can Diabetes Heal?- From Observations to Perspectives
Current Diabetes Reviews